1
|
Maagensen H, Hædersdal S, Krogh J, Hansen T, Knop FK, Thuesen ACB, Vilsbøll T. Clinical effects of SGLT2 inhibitors in seven persons with HNF1A-MODY (MODY3). Diabet Med 2024:e15387. [PMID: 38875310 DOI: 10.1111/dme.15387] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/12/2024] [Revised: 05/31/2024] [Accepted: 06/04/2024] [Indexed: 06/16/2024]
Affiliation(s)
- Henrik Maagensen
- Copenhagen University Hospital-Steno Diabetes Center Copenhagen, Herlev, Denmark
- Center for Clinical Metabolic Research, Copenhagen University Hospital-Herlev and Gentofte, Hellerup, Denmark
| | - Sofie Hædersdal
- Copenhagen University Hospital-Steno Diabetes Center Copenhagen, Herlev, Denmark
- Center for Clinical Metabolic Research, Copenhagen University Hospital-Herlev and Gentofte, Hellerup, Denmark
| | - Jesper Krogh
- Copenhagen University Hospital-Steno Diabetes Center Copenhagen, Herlev, Denmark
- Department of Medicine, Clinic for Pituitary Disorders, Zealand University Hospital, Køge, Denmark
| | - Torben Hansen
- Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
| | - Filip Krag Knop
- Copenhagen University Hospital-Steno Diabetes Center Copenhagen, Herlev, Denmark
- Center for Clinical Metabolic Research, Copenhagen University Hospital-Herlev and Gentofte, Hellerup, Denmark
- Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
| | - Anne Cathrine Baun Thuesen
- Copenhagen University Hospital-Steno Diabetes Center Copenhagen, Herlev, Denmark
- Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
| | - Tina Vilsbøll
- Copenhagen University Hospital-Steno Diabetes Center Copenhagen, Herlev, Denmark
- Center for Clinical Metabolic Research, Copenhagen University Hospital-Herlev and Gentofte, Hellerup, Denmark
- Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
| |
Collapse
|
2
|
Yuyama Y, Kawamura T, Hotta Y, Nishikawa-Nakamura N, Hamazaki T. Treatment strategy for maturity-onset diabetes of the young 3 (MODY3): Experience with two sisters and their mother. Clin Pediatr Endocrinol 2023; 32:228-234. [PMID: 37842141 PMCID: PMC10568571 DOI: 10.1297/cpe.2022-0074] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/21/2022] [Accepted: 07/23/2023] [Indexed: 10/17/2023] Open
Abstract
Maturity onset diabetes of the young (MODY) is a relatively young-onset diabetes mellitus with an autosomal dominant inheritance. Among these phenotypes, MODY3, caused by mutations in HNF1A, is one of the most frequent. Although MODY3 is known to respond markedly to sulfonylureas (SU), many cases require insulin therapy. However, there are no clear guidelines for factors to consider when introducing antidiabetic drugs and insulin. This report describes a familial case in which an older sister was diagnosed with diabetes and subsequently with MODY3, followed by the onset of diabetes in the younger sister and mother. The elder sister initially denied insulin treatment and exhibited a suboptimal response to SU but finally agreed to insulin use. The mother initially selected insulin therapy because of the challenges associated with adherence to strict dietary therapy. Conversely, the younger sister responded positively to SU and maintained effective glycemic control. The management of MODY3, even though they have the same single-gene mutation and similar residual insulin secretion at diagnosis, should be flexibly individualized for each family member to ensure long-term adherence and appropriate glycemic control.
Collapse
Affiliation(s)
- Yoshihiko Yuyama
- Division of Pediatrics, Osaka Metropolitan University Graduate School, Osaka, Japan
| | | | - Yuko Hotta
- Division of Pediatrics, Osaka Metropolitan University Graduate School, Osaka, Japan
| | | | - Takashi Hamazaki
- Division of Pediatrics, Osaka Metropolitan University Graduate School, Osaka, Japan
| |
Collapse
|
3
|
Bonner C, Saponaro C. Where to for precision treatment of HNF1A-MODY? Diabetologia 2022; 65:1825-1829. [PMID: 35412067 DOI: 10.1007/s00125-022-05696-4] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/23/2021] [Accepted: 02/16/2022] [Indexed: 11/03/2022]
Affiliation(s)
- Caroline Bonner
- Inserm, CHU Lille, Institut Pasteur de Lille, University of Lille, Lille, France.
| | - Chiara Saponaro
- Inserm, CHU Lille, Institut Pasteur de Lille, University of Lille, Lille, France
| |
Collapse
|
4
|
Comments on “Is there a Role for Bariatric Surgery in Patients with Severe Obesity in Type 1 Diabetes Mellitus?” or surgical prospects to treat 5 clusters of diabetes. Surg Obes Relat Dis 2022; 18:e21-e22. [DOI: 10.1016/j.soard.2022.01.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/26/2021] [Revised: 01/02/2022] [Accepted: 01/04/2022] [Indexed: 10/19/2022]
|